Log In
BCIQ
Print this Print this
 

Vadadustat (formerly AKB-6548)

  Manage Alerts
Collapse Summary General Information
Company Akebia Therapeutics Inc.
DescriptionOral hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN) inhibitor
Molecular Target Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN)
Mechanism of ActionHypoxia-inducible factor prolyl hydroxylase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$350.0M

$40.0M

$250.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/14/2015

$350.0M

$40.0M

$250.0M

Get a free BioCentury trial today